Tumores estromales gastrointestinales: enfoque actual. Presentación de seis casos
Palabras clave:
tumores estromales gastrointestinales, inmunohistoquímica, 50 campos de alto poder, hemorragia de vías digestivas, tomografía computarizada, c-Kit, CD34, actina de músculo lisoResumen
Se presentan seis pacientes con diagnóstico inmuno-histoquímico de tumores estromales gastrointestinales y extragastrointestinales localizados en diferentes órganos del tracto digestivo y otras áreas, estudiados e intervenidos en nuestra institución a partir del año 2000, con seguimiento en su evolución clínica hasta la fecha por los servicios de hemato- oncología y cirugía; a excepción de una paciente. En su mayoría sin diagnóstico claro en su preoperatorio o con alta sospecha de presentar tumores mesenquimales complicados por masa compresiva, oclusión intestinal o sangrado.
Se plantean de manera concreta los aspectos relevantes en su diagnóstico y clasificación patológica, manejo quirúrgico y tratamiento en relación a la literatura actual, exponiendo algunas de las controversias existentes. Además de fijar nuestra posición como grupo terapéutico frente a esta neoplasia, con base en la revisión realizada y nuestra limitada experiencia.
Descargas
Referencias bibliográficas
2. Hirota S, Isozaki K, Moriyama Y, et al. Lancet Oncol 2002; 3: 655-662.
3. Lecoin L, Gabella G, Le Douarin N. Origin of the c-kit-positive interstitial cells in the avian bowel. Development. 1996; 122 (3): 725-733.
4. Maeda H, Yamagata S, Nishikawa S, et. Al. Requirement of c-kit for development of intestinal pacemaker system. Development. 1992; 116: 369-374.
5. Young HM, Ciampoli D, Southwell BR, Newgreen DF: Origin of interstitial cells of Cajal in the mouse intestine. Dev Biol 1996, 180:97-107.
6. Kinblom LG, Remotti HE, Aldenborg F. Lancet Oncol 2002; 3: 655-662.
7. Alvarado CI, Ramírez BL, et al. Tumor estromal gástrico con degeneración mixoide. Rev. Gastroenterol Mex 2000; 65(1): 22-25.
8. Vliagoftis H, Worobec AS, Metcalfe DD. The protooncogene c-kit and c-kit ligand in human disease. J Allergy Clin Immunol 1997;100:435-440.
9. De Silva CM, Reid R, et al. Gastrointestinal stromal (GIST): C-Kit mutations, CD 117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003; 9.
10. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
11. Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas and leimyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25: 1121-1133.
12. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998; 115: 1090-1095.
13. Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41-47.
14. De Silva CM, Reid R, et al. Gastrointestinal stromal (GIST): C-Kit mutations, CD 117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003; 9.
15. Miettinen M, Lasota J. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
16. Heinrich MC, Blanke CD, Druker BJ, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
17. Hornick JL, Fletcher CDM. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
18. Miettinen M, El-Rifai W, Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Human Pathology. 2002; 33 (5): 478-483.
19. Joensuu H, Fletcher Ch, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655-64.
20. Reith J, Goldblum J, Lyles R, Weiss S. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000; 13 (5): 577-585.
21. Miettinen M, Lasota J. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
22. Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endotelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol. 2000; 13 (5): 536-541.
23. Sánchez FP, Martínez JL, Blanco B. Tumor del estroma gastrointestinal con afección a estómago. Presentación de un caso y revisión de la literatura. Rev Gastroenteral Mex 1999; 64: 139-142.
24. Fletcher CDM, Berman JJ, Corless C, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
25. Emory TS, Sobin LH, Lukes L, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
26. Fletcher C, Berman J, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. International Journal of Surgical Pathology. 2002; 10 (2): 81-89.
27. Miettinen M, Furlong M, Sarolomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas in the rectum and anus: a clinicopathologic, inmunohistochemical and molecular genetic study of 144 cases. Am J Surg Pathol. 2001; 25: 1121-1133.
28. Ueyama T, Guo K-J Hashimoto H, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
29. Emory TS, Sobin LH, Lukes L, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
30. Goldblum JR, Appelman HD. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
31. Brainard JA, Goldblum JR. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
32. Tworek JA, Appelman HD, Singleton TP, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
33. Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
34. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
35. Hirota S, Isosaki K, Moriyama Y, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
36. Miettinen M, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
37. Kindblom LG, Remotti HE, Aldenborg F, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
38. Miettinen M, Sobin LH, Sarlomo-Rikala, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
39. Emory TS, Derringer GA, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Human Pathol 2002; 33: 478-481.
40. De Silva C, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cáncer therapy with Imatibin. Pathol Oncol Res. 2003; 9 (1): 13-19.
41. Pidhrecky J, Cheney RT, Kraybill WG, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
42. Ishida T, Wada I, Horiuchi H, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
43. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
44. Cooper PN, Quirke P, Hardy GJ, et al. Gastrointestinal stromal tumors (GIST): C-Kit mutations, CD 117 expression, differential diagnosis and targeted cancer therapy with imatinib. Gastrointestinal stromal tumors 2003; 9: 13-18.
45. Cunningham RE, Federspiel BH, McCarthy WF, Sobin, LH, O'Leary TJ. Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histologic evaluation, flow cytometry, and image cytometry. Am J Surg Pathol. 1993 Jun;17(6):588-594.
46. Miettinen M, Sarlomo-Rikala M, Sobin. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24(10):1339-52.
47. Bravo M, Adrada A, Sandoval J. Tumor estromal epiteloide quístico de crecimiento exogástrico. Rev Colomb Cir 2001; 106-110, Ilus.
48. Miettinen M, Sarlomo-Rikala M, Lasota J. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
49. Michael C, Heinrich MC, Brian P, et al. Biology and genetic aspects of gastrointestinal stromal tumors: kit activation and cytogenetic alterations. Human Pathol 2002; 33: 484-493.
50. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg 1992; 215: 68-77.
51. DeMatteo RP, Heinrich MC, El-Rifai W, et al. Clinical management of t gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-662.
52. Mudan SS, Conlon KC, Woodruff JM, et al. Management of malignant gastrointestinal stromal tumors: before and after STI571. Human Pathol 2002; 33: 466-477.
53. Joensuu H, Roberts PJ, Sarolo-Rikala M, et al. Effect of tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
54. Appelman HD. Mesenchymal tumors of the gut: histological perspectives new approaches, new results, and does it make any different. Monogr Pathol 1990; 31: 220-246.
55. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective detabase. Ann Surg Oncol 2001; 8: 50-59.
56. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL, tyrosine kinase in chorinc myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
57. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
58. Heinrich MC, Coless CL, Blanke C, et al. Kit mutations status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Clin Oncol 2002; 21: (2a) abstr.
59. Van Ossterom AT, Judson I, Wermeij J, et al. safety and efficacy of imatinib mesylate (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358: 1421-1423.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Todos los textos incluidos en la Revista Colombiana de Cirugía están protegidos por derechos de autor. Las opiniones expresadas en los artículos firmados son las de los autores y no coinciden necesariamente con las de los directores o los editores de la Revista Colombiana de Cirugía. Las sugerencias diagnósticas o terapéuticas como elección de productos, dosificación y métodos de empleo corresponden a la experiencia y al criterio de los autores.